Resistance of Gram-positive pathogens to first-line antimicrobial agents has been increasing in many parts of the world. We compared the in vitro activities of torezolid with those of other antimicrobial agents, including linezolid, against clinical isolates of major aerobic and anaerobic bacteria. Torezolid had an MIC 90 of <0.5 g/ml for the Gram-positive bacterial isolates tested and was more potent than either linezolid or vancomycin.
Resistance of Gram-positive pathogens to first-line antimicrobial agents has been increasing in many parts of the world. We compared the in vitro activities of torezolid with those of other antimicrobial agents, including linezolid, against clinical isolates of major aerobic and anaerobic bacteria. Torezolid had an MIC 90 of <0.5 g/ml for the Gram-positive bacterial isolates tested and was more potent than either linezolid or vancomycin.
Antimicrobial resistance in Gram-positive cocci has become a major problem in recent years. Oxazolidinones, a new therapeutic class of synthetic drugs, are active against Gram-positive pathogens. Linezolid, the only marketed oxazolidinone, inhibits the initiation of bacterial protein translation by binding to the 23S rRNA peptidyl transferase region (15) . The widely used drug linezolid is effective against most Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus spp., and penicillin-resistant Streptococcus pneumoniae (1, 2) . However, several recent studies have reported the emergence of linezolid-resistant staphylococci and enterococci in Brazil, China, France, Germany, Italy, and Sweden. The dominant resistance mechanisms are mutations of the 23S rRNA gene and the recently described mobile chloramphenicol-florfenicol resistance (cfr) methyltransferase gene (9) .
The antibacterial activity of oxazolidinones depends on their affinity for the site of action on the ribosome. Therefore, by modifying their chemical structure, novel oxazolidinones with improved antimicrobial activity can be obtained. Accordingly, it is important to find more useful and less toxic oxazolidinones. Torezolid [TR-700, DA-7157; R-3-(4-(2-(2-methyltetrazol-5-yl)pyridine-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-on] is the active moiety of the prodrug torezolid phosphate (TR-701, DA-7218) (Fig. 1) . In a recent study, torezolid was 4-to 8-fold more active than linezolid against Grampositive bacteria collected from the United States (3). In another study, torezolid demonstrated an 8-to 16-fold increase in potency against all of the linezolid-resistant isolates tested, including MRSA, MRSA carrying the mobile cfr methyltransferase gene, and vancomycin-resistant enterococci (14) . However, as far as we know, the activities of torezolid against anaerobic bacteria have not been reported.
Human plasma protein binding of torezolid was about 80% (data not shown), and the MIC was unaffected by the presence of 20% human plasma (4) . Torezolid has a better pharmacokinetic profile than linezolid. After oral administration of torezolid at 200 mg once a day, the maximum concentration of the drug in serum, half-life, and area under the curve were 2.0 g/ml, 11.2 h, and 25.4 g ⅐ h/ml, respectively (13) . In another study, torezolid phosphate was safe and effective with once-daily 200-mg dosing over 5 to 7 days of treatment for severe complicated skin and skin structure infections caused by Gram-positive bacteria (16) . In this study, we compared the in vitro activities of torezolid with those of other antimicrobial agents, including linezolid, against clinical isolates of major aerobic and anaerobic Gram-positive and Gram-negative bacteria.
(Part of this study was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004 [12] ).
Five hundred ten nonduplicate aerobic and anaerobic bacterial isolates were collected between 2002 and 2004 from patients at a South Korean tertiary-care hospital. The species were identified by conventional methods or by using either the ID 32 GN or the ATB 32A system (bioMérieux, Marcyl'Etoile, France). Antimicrobial susceptibility was tested by the CLSI agar dilution method (5, 6, 7 
